• Heart Failure
  • Cardiovascular Clinical Consult
  • Adult Immunization
  • Hepatic Disease
  • Rare Disorders
  • Pediatric Immunization
  • Implementing The Topcon Ocular Telehealth Platform
  • Weight Management
  • Monkeypox
  • Guidelines
  • Men's Health
  • Psychiatry
  • Allergy
  • Nutrition
  • Women's Health
  • Cardiology
  • Substance Use
  • Pediatrics
  • Kidney Disease
  • Genetics
  • Complimentary & Alternative Medicine
  • Dermatology
  • Endocrinology
  • Oral Medicine
  • Otorhinolaryngologic Diseases
  • Pain
  • Gastrointestinal Disorders
  • Geriatrics
  • Infection
  • Musculoskeletal Disorders
  • Obesity
  • Rheumatology
  • Technology
  • Cancer
  • Nephrology
  • Anemia
  • Neurology
  • Pulmonology

COVID-19 Vaccines Reduce Risk of Cardiac, Thromboembolic Outcomes: Daily Dose

COVID-19 Vaccines Reduce Risk of Cardiac, Thromboembolic Outcomes: Daily Dose / Image Credit: ©New Africa/AdobeStock
©New Africa/AdobeStock

Patient Care brings primary care clinicians a lot of medical news every day—it’s easy to miss an important study. The Daily Dose provides a concise summary of one of the website's leading stories you may not have seen.

Last week, we reported on findings from a study published in Heart that examined the association between COVID-19 vaccination and the risk of post-COVID-19 cardiac and thromboembolic complications.

The study

Investigators conducted a staggered cohort study using electronic health records of 10.17 million vaccinated and 10.39 million unvaccinated individuals aged 18 years or older with no previous SARS-CoV-2 infection or COVID-19 vaccine at baseline based on national COVID-19 vaccination campaigns in the United Kingdom, Spain, and Estonia from January 2021 to July 2021.

Researchers used vaccination status as a time-varying exposure and included all COVID-19 vaccines approved within the study period: ChAdOx1 (Oxford/AstraZeneca), BNT162b2 (BioNTech/Pfizer), Ad26.COV2.S (Janssen), and mRNA-1273 (Moderna).

Outcomes included HF, VTE, and ATE recorded in 4 different time periods following SARS-CoV-2 infection: 0–30 days (acute phase), 31–90 days, 91–180 days, and 181–365 days (post-acute phase).

The findings

Results showed that COVID-19 vaccination was associated with reduced risks of post-COVID-19 cardiac and thromboembolic outcomes in the acute (0-30 days) and post-acute (31-365 days) phase, with the effect being stronger in the acute phase.

Investigators noted that the meta-analytic sHR for post-COVID VTE was 0.22 (95% CI, 0.17–0.29), ATE was 0.53 (95% CI, 0.44-0.63), and HF was 0.45 (95% CI, 0.38-0.53) for 0-30 days, while in the 91-180 days sHR were 0.53 (95% CI, 0.40-0.70), 0.72 (95% CI, 0.58-0.88), and 0.61 (95% CI, 0.51-0.73), respectively.

Authors' comment

"Findings from this study highlight yet another benefit of COVID-19 vaccination. However, further research is needed on the possible waning of the risk reduction over time and on the impact of booster vaccination."

Click here for more details.

Related Videos
"Vaccination is More of a Marathon than a Sprint"
Vaccines are for Kids, Booster Fatigue, and Other Obstacles to Adult Immunization
New Research Amplifies Impact of Social Determinants of Health on Cardiometabolic Measures Over Time
© 2024 MJH Life Sciences

All rights reserved.